Nantkwest Inc (NASDAQ: NK) is flying early on in the trading session this morning, and for good reason. The company released data from the first 300 doses in the first in-human trial of CD16. As you could imagine, the data was positive, exciting investors and sending the stock on a run for the top. Today, we’ll talk about:
- The results;
- what we’re seeing from NK stock as a result; and
- what we’ll be watching for ahead.
NK Announces Clinical Results
As mentioned above, Nantkwest is having a great start to the trading session this morning after releasing clinical data. The data came from the first in human trial of CD16 targeted therapy.
During the trial, the company is assessing CD16 in 30 patients with advanced metastatic cancer refractory to multiple therapies. In the release, NK said that the first 300 doses among 30 patients came with zero incidence of Cytokine Release Syndrome. Also, all patients received the NK Cell Infusion in combination with a novel cancer memory vaccine as outpatients. None of these patients had immune-related adverse events.
The company also said that in highly refractory late stage advanced metastatic triple negative breast cancer, the treatment led to 80% disease control. Those with highly refractory late-stage advanced metastatic pancreatic cancer experienced 90% disease control with median overall survival of 9.5 months.
In a statement, Dr. Patrick Soon-Shiong, Chairman and CEO at NK, had the following to offer:
High dose, uninformed, toxic chemotherapy damages the immune system and induces what is known as tolerogenic cell death. Natural Killer cells are the core innate immuno-protective mechanism against cancer. By developing a system of activating the patient’s own Natural Killer cells and T cells, as well as augmenting the patient’s NK killing ability with engineering off-the- shelf NK transfusions, we hypothesize that resistant cancer can be overcome. We believe that current checkpoint inhibitors alone are insufficient to achieve long-term remission and only by inducing both the innate and adaptive immune system, and by orchestrating the treatment in a temporal-spatial sequence, will we induce T cell memory and long-term durable response. These early results of 300 doses of the Cancer Memory Vaccine in 30 patients over the course of the last 14 months are encouraging and suggest that we may be on the correct path to a paradigm change, leading ultimately to a chemo-free treatment of cancer patients, early in the course of their disease and ultimately to a path of cancer prevention.
What We’re Seeing From The Stock
When we start to work in the market, one of the first lessons that we learn is that it’s important to keep a close eye on the news. After all, it’s the news that moves the market. In the case of Nantkwest, the news proved to be overwhelmingly positive. After all, the company’s experimental treatment is producing promising results. So, it comes as no surprise to see that excited investors are pushing the stock on a run for the top. At the moment (9:48), NK is trading at $3.79 per share after a gain of $1.08 per share or 39.85% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NK. In particular, we’re interested in following the story surrounding the company’s continued work to bring this cancer treatment to patients in need as it seems to be producing great results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!